NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) remains negative
Q1 FY2026 property, plant & equipment (net) was $936K, compared with $0 a year earlier.
Context
- Property, plant & equipment (net) amounted to 7.9% of total assets at the end of Q1 FY2026, up 7.9 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 633K USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 633K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 property, plant & equipment (net) of $936K is the 5th highest of the 9 companies compared; the peer median is $1.02M.
- Property, plant & equipment (net) amounts to 7.9% of total assets for NRXP, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $68.58M | -21.9% | -16.0% | 21.0% | |
| Mar 2026 | $4.5M | -22.4% | -14.2% | 3.4% | |
| Mar 2026 | $3.61M | -12.3% | -26.1% | 11.7% | |
| Jun 2026 | $1.26M | -88.6% | -17.2% | 5.2% | |
| Mar 2026 | $936K | — | — | 7.9% | |
| Mar 2026 | $781K | +52.2% | -25.4% | 1.2% | |
| Mar 2026 | $595K | -31.5% | -21.9% | 1.1% | |
| Mar 2026 | $198.98K | -20.6% | +47.4% | 0.9% | |
| Mar 2026 | $89.25K | +48.5% | -36.4% | 0.5% | |
| Peer median (excluding NRXP) | $1.02M | -21.2% | -19.6% | 2.3% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.